Member Info for tomvisual

What are the fda sensitivity and specificity requirements??
Milcait can you reference the David Wilson article he wrote that you mentioned in your post?

https://www.forbes.com/sites/williamhaseltine/2020/06/19/immunity-to-covid-19-infection-may-fade-quickly/
Nature Medicine indicates that immunity to infection by SARS-CoV-2 may fade quickly, at least in people with no or moderate symptoms.
The first unexpected finding is that CAT-scans of the lung showed that two-thirds of those with no clinical signs of Covid-19 had what are called ground-glass opacity abnormalities typical of Covid-19 in at least one lung, and one-third showed ground-glass opacities in both lungs. In simple terms, SARS-CoV-2 is damaging the lungs of the majority who seem symptom-free. The long term health effects of such injuries may be apparent in later life.
A second somewhat unexpected finding is that the virus load upon initial detection was indistinguishable between the two infected groups. At least in the early stages of infection, the amount of virus detected in nasal swabs is not an indication of subsequent disease progression.
Viral RNA was detected in the nasal swabs of those infected for an average of 19 days in those with no clinical symptoms and 14 days for those who fell ill. Viral RNA was present as long a 45 days in one asymptotic individual and up to 22 days in a symptomatic patient. Detection of viral RNA may not be equivalent to the shedding of live virus. Nonetheless, the possibility is not excluded that transmission may extend past the usual quarantine period of 14 days. In recent times people in Northern China may be quarantined for up to 21 days post-exposure.

Is the AGM on line?

140 close on Google

TW = Tom Winnifrith

https://www.tomwinnifrith.com

AVACTA RNS
https://www.investegate.co.uk/avacta-group-plc/rns/update-on-affimer--therapy-for-covid-19-infection/202006180700062969Q/

Could not resist asking the following question:
how is the Avacta PoC diagnostic test progressing?

Typed response:
Avacta will update the markets on progress with development of its SARS-CoV-2 Ag test at the appropriate times during product development

David Wilson ...
we know we can do it ....
For me, I would go so far to say that this confirms to me that Avacta have a LFD.
What is the sensitivity and specificity???

PL75, I am registered. I make it 8pm. Asking for confirmation ....
Did I calculate the start time correctly?? 8pm 17/6/20?

What time is the webinar on 17/6/20?
Is the Webinar something that has been planned for weeks, or has it been hastily set-up to address the delay in Cytiva developing a PoC diagnostic test?

Cytiva have a webinar planned for wed 17/6/20.

https://www.labroots.com/webinar/panel-discussion-critical-design-considerations-covid-19-rapid-poc-diagnostic-test-development.

"This session will discuss the design challenges encountered during COVID-19 rapid point of care (POC) diagnostic test development"
Note use of PAST tense.
Also from Alistair Smith presentation "prototype ready end of June followed by testing".
Will we get an RNS before Wednesday's webinar??

Any one have the link to cyvita webinar?

PL75 : can you advise whats next on the list?
No doubt this will be update after presentation on Thursday.

Good thing about BAMS test is no reliance on difficult to procure reagents.
Mass spectrometers are expensive. Does every hospital have one? Lots of other Companies and Universities purchase them for Chemical analysis. Could the US and UK Mass Spectrometer Companies provide input into the "war"/research effort to assist with testing/automation protocols?

Judging by the fall in Avacta's share price, it looks as if some investors are interpreting the 'progress is being made' statements, rather than a 'here it is and it has been approved and it is being rolled out' statement, as holding type statements perhaps indicating difficulties that were not forseen by Avacta.
Also, a paranoid person might take what sounds like a very positive development, that the nucleocapsid protein is another target that can be detected, as an indication that the spike protein test is not sensitive enough.
However, I am inclined to give Avacta the benefit of the doubt, as they have convinced several partners to devote considerable effort to the Affirmer approach and these are organisations with expertise.
As a rapid PoC Antigen test, which is manufacturable in huge numbers, which is what Avacta has a good chance of achieving, is what is needed to get back to something like normaility, then the upside for Avacta is huge.
I will continue to keep an eye on Avacta to see whether I can buy cheaper.
Test, test, test

Rns link?

R4 Today, 6:26: Interesting that AZN have lodged a takeover bid for Gilhead Science but at an unrealistic price.
AZN have been very proactive during the covid19 pandemic. No doubt Avacta will be of interest to AZN if Avacta deliver!! Moreover perhaps if affimers bypass patents associated with antibodies.

Invested here. Came across DM article.
Professor claims only 10% of coronavirus patients develop antibodies meaning it may never be possible to measure true scale of pandemic
https://www.dailymail.co.uk/news/article-8396195/Professor-says-10-people-coronavirus-develop-antibodies.html
Is this a new take in things? A lot of effort on Antibody testing could be 'barking up the wrong tree'.
The final paragraph:
" Professor Dalgleish said:  'I propose a vaccine that uses T cells. We have a T cell boosting vaccine in cancer patients and none of them, even those over 70, get viral infections.'"
Also, if there is a PoC way to measure T Cell activity against Covid-19, could this be a really useful test?
Are we scuppered??

No placing. Funded. Read info previously posted on board.

Managed a limit order a purchase at 134.99p. Very pleased with this.